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EXPLORING THE POTENTIAL YIELD OF PRENATAL TESTING BY EVALUATING A 
POSTNATAL POPULATION WITH STRUCTURAL ABNORMALITIES 
Abstract 
Peyton Bree Busby, BS 
Advisory Professor: Blair K. Stevens, MS, CGC 
 
After identification of one or more structural abnormalities in a fetus, pregnant 
women are offered a host of different testing options to identify a possible genetic cause 
for the structural abnormality(ies). When considering what type of test to undertake, 
there is limited information on the diagnostic yield of the varying testing options. Some 
women may miss an opportunity to gain the information they are seeking or make a less 
informed decision when they choose a testing option after identification of a structural 
abnormality due to this lack of information. This study aimed to identify the potential 
diagnostic yield of all currently available prenatal testing options in the presence of a 
structural abnormality through a retrospective chart review of a postnatal population of 
infants with structural abnormalities. Of 791 patients with at least one structural 
abnormality, 691 patients underwent genetic testing and 222 had a genetic aberration 
that explained their phenotype. Chromosomal microarray had the highest potential 
diagnostic yield across the entire cohort and among individuals with multiple structural 
abnormalities, 26.8% (95% CI: 23.5 - 30.3) and 29.0% (95% CI: 25.3 - 33.3) 
respectively, which reached significance (p <0.001, p = 0.029) compared to all of the 
other prenatal screening and diagnostic options. In the isolated cohort, whole exome 
sequencing had a higher potential diagnostic yield of causative pathogenic aberrations, 
followed by chromosome microarray. Expanded non-invasive prenatal testing (NIPT with 
microdeletions and whole genome NIPT) had a higher potential yield than traditional 
NIPT. Whole genome NIPT also had a comparable yield as a karyotype, although this 
did not reach statistical significance. While interesting, it is important to consider the 
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limited data available on expanded NIPT panels compared to the robust studies of 
traditional NIPT and how this might affect these results and post-test counseling 
regarding positive screening results. This study provides further evidence for the use of 
chromosomal microarray for the highest potential diagnostic yield in genetic testing after 
identification of one or more structural abnormalities.   
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Introduction 
Structural abnormalities occur in 3-5% of all pregnancies and have a wide range 
of prognoses and etiologies [1]. Structural abnormalities (birth defects) are differences in 
fetal development that can affect any organ in the body [1]. Understanding the etiology 
of a structural abnormality allows for more accurate counseling regarding prognosis, 
pregnancy and neonatal management, and recurrence risks for future children. Common 
genetic etiologies include aneuploidy such as Down syndrome, copy number variants 
(CNVs) such as 22q11 deletion syndrome, and single gene disorders such as Noonan 
syndrome. Due to the association between genetic conditions and structural 
abnormalities, women are offered a host of different genetic testing options upon 
identification of an ultrasound abnormality. Testing options can include diagnostic testing 
via chorionic villus sampling (CVS) or amniocentesis, or for those who decline diagnostic 
testing, a variety of non-invasive prenatal testing (NIPT) options.  
Diagnostic testing is clearly superior to screening tests when evaluating for 
genetic abnormalities as it allows for more comprehensive and more accurate testing, 
but these benefits must be weighed against procedure related risks. 
When a diagnostic procedure is performed, a multitude of genetic tests can be 
ordered, such as karyotype, chromosomal microarray (CMA), and next-generation 
sequencing for single gene disorders. When offering prenatal testing after identification 
of a structural abnormality, there is limited information available on the diagnostic yield of 
each testing option to aid providers and patients in counseling and decision-making. 
Benn et al. found that when the indication for prenatal testing is a structural anomaly, a 
karyotype will detect an abnormality in 16.7% of pregnancies that undergo diagnostic 
testing [3]. Donnelly et al. found in karyotypically normal pregnancies, chromosome 
microarray detected an abnormality in an additional 5.6% of cases with one structural 
anomaly and 13.0% of cases with more than one structural anomaly [4]. There have 
been multiple studies (with differing inclusion criteria and testing strategies) looking at 
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the potential yield of prenatal WES, producing a wide diagnostic yield range from 6.2-
80% that generally falls within the 15-45% range [5-8]. Although these studies provide 
some information about the yield of diagnostic testing options, many are limited 
regarding the specific type of structural abnormality, and do not include any comparison 
to the rapidly expanding NIPT options [5] [9]. 
The detection rate of NIPT for common aneuploidies (13, 18, 21, X, and Y) range 
between 91.7%-99.9% [11]. In addition to common aneuploidy, expanded NIPT panels 
are currently clinically available that include options such as screening for other 
chromosome aneuploidies, select microdeletions, genome-wide deletions or duplications 
greater than 7Mb and certain autosomal dominant single gene disorders [12-14]. The 
detection rates for these additional conditions are lower, ranging between 60-85% for 
specific CNVs and 43-99% for select single gene disorders [12-14]. However, peer-
reviewed publications on the accuracy of NIPT for CNVs and single gene disorders is 
limited and peer reviewed data has yet to be published.  
Many studies on expanded NIPT (NIPT for common microdeletions, whole 
genome NIPT, and NIPT for single gene disorders) do not have outcome data for all 
pregnancies tested, and often have a small number of positive results with multiple false 
positives [13-17]. This leads to vastly different quoted detection rates and confidence 
intervals for conditions within a specific tests and across different testing platforms [12-
17].  
Screening tests such as NIPT are desirable to patients because they do not pose 
a risk for miscarriage to the pregnancy, but they are not diagnostic and only screen for a 
limited number of conditions. Therefore, the American College of Obstetrics and 
Gynecology does not recommend the use of cell-free fetal DNA screening tests after the 
identification of a structural abnormality on ultrasound [18].  
Despite these recommendations, many women decline diagnostic testing and opt 
for NIPT. Since the introduction of NIPT, the rate of invasive testing for all indications 
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has decreased significantly, by as much as 53% and 77% for amniocentesis and CVS 
respectively [19]. The rate of invasive testing is predicted to continue to decline by as 
much as 91% as predicted by some models [20]. Many women indicate their choice of 
NIPT is influenced by its high detection rates [21]. However, data has shown that 
patients overestimate the accuracy of NIPT for Down syndrome and overestimate the 
number of conditions NIPT can screen for [22]. It is also unclear if women who have a 
fetus with a structural abnormality also use this same reasoning when electing NIPT, as 
there have not been extensive studies in this particular patient population.  
Few studies have evaluated the utility of NIPT in the presence of congenital 
anomalies. One retrospective study evaluated 251 pregnancies with NIPT results and 
abnormal ultrasound findings, including multiple anomalies, isolated anomalies, 
increased nuchal translucency (>3.5mm), soft markers, and growth restriction [23]. NIPT 
identified 26 genetic aberrations in this population. Thirty three of the 224 patients with 
negative NIPT underwent diagnostic testing postnatally, which identified an additional 7 
aberrations missed by NIPT [23]. Over half of the study population had increased nuchal 
translucency and soft signs, which are associated mostly with aneuploidy and therefore 
more likely to be detected by NIPT [23]. Another study by Sotiriadis et al. [24] evaluated 
the potential yield of NIPT for common aneuploidies on prenatal CMA samples from 
pregnancies identified as having one or more structural abnormalities. Only 7 of the 22 
aberrations identified on CMA would have been picked up by NIPT for common 
aneuploidies, and only one of the fifteen other aberrations would have potentially been 
picked up by NIPT plus common microdeletions [24].  
This study aims to address the gap in the literature concerning the yield of 
prenatal testing after identification of specific structural abnormalities, particularly for 
newer tests such as cell-free DNA screening for single gene disorders and diagnostic 
sequencing tests. This information will allow for a better understanding of the likelihood 
of detecting an underlying genetic condition or an increased risk for a condition by each 
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prenatal test and ultimately facilitate more accurate genetic counseling and more 
informed decision making. 
 
Methods 
Inclusion and Exclusion Criteria 
Individuals for this study were selected from a database of patients maintained 
by the Division of Medical Genetics in the Department of Pediatrics at McGovern 
Medical School at the University of Texas Health Science Center at Houston (UTHealth). 
The database consists of patients seen by the UTHealth Medical Genetics team since 
January of 2014. Protocol was submitted to the University of Texas Health Science 
Center Internal Review Board and Memorial Hermann Internal Review Board and was 
approved on June 12th, 2018 and September 11th, 2018 respectively (HSC-MS-18-0458).  
Data from the clinical database was abstracted into a study database created in 
Qualtrics (Qualtrics, Provo, UT) and exported to Stata (v13.1, College Station, TX) for 
analysis.  
Patients listed in the database were included in the study if, 1) they were initially 
seen by the genetics team as an inpatient consult at Children’s Memorial Hermann 
Hospital, in Houston, Texas, 2) initial consult occurred from January 1st, 2014 through 
December 31st, 2017, 3) consulted within the first 6 months of life, 4) review of clinical 
records demonstrated evidence of at least one structural abnormality potentially 
detectable by ultrasound. Patients with only structural abnormalities that are not 
potentially detectable by prenatal ultrasound were excluded. 
Once patients in the database satisfied inclusion criteria 1-3, their inpatient and 
outpatient medical records were reviewed from the corresponding electronic medical 
record systems (EMR). Only patients with a structural abnormality potentially detectable 
by ultrasound were included in the statistical analysis. Abnormalities not potentially 
detectable by prenatal ultrasound were excluded. Data on genetic testing results was 
5 
 
obtained from both the inpatient and outpatient EMR systems. When available, 
information regarding the reason for lack of testing was recorded.  
 
Structural abnormalities 
A list of structural abnormalities to be included in the analysis was generated 
from a previous study comparing CMA and karyotype in the presence of structural 
abnormalities [4] and from internal lists of structural abnormalities at the Children’s 
Memorial Hermann Fetal Center. Structural abnormalities were determined to be either 
potentially detectable by ultrasound or not by two maternal fetal medicine specialists with 
a total of 37 years of experience in the field.  
 
Determination of potential diagnostic yield of prenatal testing options 
Appropriate Prenatal Test for Condition 
The potential diagnostic yield of prenatal testing was determined first by 
evaluating whether the genetic conditions detected in our study population could have 
been detected by clinically available prenatal screening and diagnostic tests. Diagnostic 
testing options included in the analysis include aneuploidy fluorescence in situ 
hybridization (FISH), karyotype, chromosomal microarray (CMA), next-generation 
sequencing (NGS) panels, prenatal WES, methylation studies, and trinucleotide repeat 
analysis. Screening options included a variety of non-invasive prenatal testing (NIPT) 
screens, which are outlined in Table 1.  
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Table 1: Non-invasive prenatal screening options included in this study 
Prenatal screening option Conditions screened for  
NIPT for common aneuploidies 
(NIPT) 
Aneuploidy for chromosomes 13, 18, and 21 
NIPT + sex chromosome 
abnormalities (NIPT+SCAs) 
Aneuploidy for chromosomes 13, 18, 21, and X and Y 
NIPT + common 
microdeletions/copy number 
variants (NIPT+CNVs) 
Aneuploidy for chromosomes 13, 18, 21, X, and Y and 
common microdeletion syndromes 22q11.2 deletion 
syndrome (DiGeorge syndrome), 11q- (Jacobsen 
syndrome), 5p- (Cri-du-Chat), 8q24.1- (Langer-Giedion 
syndrome), 1p36 deletion syndrome, 4p- (Wolf-
Hirschhorn syndrome),15q- (Prader-Willi syndrome; 
Angelman syndrome) 
Whole genome NIPT Identifies deletions or duplications 7Mb or greater across 
the entire genome, including aneuploidy for all 23 
chromosomes and select copy number variants 
previously described for NIPT+ common microdeletions 
NIPT for select single gene 
disorders (NIPT+ SGD) 
Identifies de novo or paternally inherited mutations in the 
following genes: BRAF, CBL, CDKL5, CHD7, COL1A1, 
COL1A2, FGFR2, FGFR3, HDAC8, HRAS, JAG1, KRAS, 
MAP2K1, MAP2K2, MECP2, NIPBL, NRAS, NSD1, 
PTPN11, RAD21, RAF1, RIT1, SHOC2, SMC1A, SMC3, 
SOS1, SOS2, SYNGAP1, TSC1, and TSC2 
 
For each genetic condition, a test was selected if it had the potential to detect the 
genetic aberration. When individuals had more than one identified genetic aberration, 
only the one that explained the phenotype was used for determination of potential 
diagnostic yield of prenatal testing.  
Patient results were classified as negative or positive. Positive results were 
further broken down into benign, possible, and causative Individuals with a possible 
classification had a finding that could potentially explain their phenotype, but at the time 
of data collection there was not a decision or resolution of the uncertainty. These 
findings included variants of uncertain significance (VUS) in genes associated with the 
phenotype or in candidate genes, CNVs identified in individuals with similar findings or 
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normal phenotype, and likely diagnoses that needed further clinical correlation that could 
not be evaluated as the patient was lost to follow up.  
When an individual had a positive finding or findings that did not explain their 
phenotype, they were included when determining the yield of that particular test in order 
to reflect the true positive rate for that test, but the individual was not counted as having 
a pathogenic variant causative of their structural abnormalities (causative genetic 
aberration).  
 
Calculating Diagnostic Yield 
To calculate the diagnostic yield for a test for causative genetic aberrations, we 
first calculated the number of patients in our dataset whose genetic aberration could 
have potentially been identified by that test (NID). This was done by dividing the number 
of patients with a causative genetic aberration that could have potentially been identified 
by the test (NPOT) by the sum of the number of patients in our dataset that had any 
causative genetic aberration identified (NCAU) and those that only had a negative, benign 
or uncertain findings on appropriate testing (NNEG). Appropriate testing was defined as 
the same test performed on the patient or a different test that would have been able to 
identify the same aberration.  
The NID was then multiplied by the detection rate of the test (DRT). For the 
screening tests, the DRT was the sum of previously reported detection rates [11-14, 26, 
27] of all the conditions that could have been identified by the test (Table 2), after taking 
into account the prevalence of that condition in our study cohort in order to account for 
the varying detection rates by condition for a particular test. Of note, the detection rate 
for triploidy was determined using two publications [19, 21], as well as the consideration 
of different rates of detection based on the origin of the extra genetic material. 
Considering 85% of triploid pregnancies are diandric and 15% are digynic, the detection 
rate for triploid pregnancy was estimated to be 97.8% using appropriate and available 
8 
 
screening methods (0.85*99%+0.15*91%=97.8%). For the diagnostic tests, the DRT 
were assumed to be 100%. Therefore, our formula for calculating the diagnostic yield 
(DY) for a test was as follows: 
𝐷𝑌 =  
𝑁𝑃𝑂𝑇
𝑁𝐶𝐴𝑈 + 𝑁𝑁𝐸𝐺
 𝑥 𝐷𝑅𝑇 
 
To determine the potential yield of testing, including individuals with benign 
findings, the same procedure was followed, except instead of calculating NPOT, we 
calculated NALL. NALL is the number of patients with a genetic aberration that could have 
potentially been identified by the test (NALL). 
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Table 2: Detection rates for prenatal screening tests by condition 
Condition Detection Rate Source 
Aneuploidies   
 Trisomy 21 99.7% (99.1 – 99.9%) [11] 
 Trisomy 18 97.9% (94.9 – 99.1%) [11] 
 Trisomy 13 99.0% (65.8 – 100%) [11] 
 Triploidy 97.80% [19, 21] 
 Monosomy X (45, X) 95.8% (70.3 - 99.5%) [11] 
 Other SCA 100% (83.6 – 100%) [11] 
Copy Number Variants   
 22q11.2 deletion (DiGeorge) syndrome 53.9% (28-91%) [14] 
 11q- (Jacobsen syndrome) 86.7% (57-99%) [14] 
 5p- (Cri-du-Chat) 83.1% (48-96%) [14] 
 8q24.1- (Langer-Giedion syndrome) 97.2% (80-99%) [14] 
 1p36 deletion syndrome 50.7% (13-81%) [14] 
 4p- (Wolf-Hirschhorn syndrome) 72.9% (37-91%) [14] 
 15q- (Prader-Willi syndrome; Angelman syndrome) 59.2% (16-74%) [14] 
 Whole Genome (>7 Mb) 95.9% (61-99%) [14] 
Single Gene Disorders   
 BRAF 96% [12] 
 CBL 86% [12] 
 CDKL5 84% [12] 
 CHD7 91% [12] 
 COL1A1 92% [12] 
 COL1A2 92% [12] 
 FGFR2 96% [12] 
 FGFR3 96% [12] 
 HDAC8 66% [12] 
 HRAS 92% [12] 
 JAG1 79% [12] 
 KRAS 96% [12] 
 MAP2K1 96% [12] 
 MAP2K2 96% [12] 
 MECP2 78% [12] 
 NIPBL 94% [12] 
 NRAS 96% [12] 
 NSD1 87% [12] 
 PTPN11 96% [12] 
 RAD21 43% [12] 
 RAF1 96% [12] 
 RIT1 96% [12] 
 SHOC2 96% [12] 
 SMC1A 96% [12] 
 SMC3 96% [12] 
 SOS1 96% [12] 
 SOS2 96% [12] 
 SYNGAP1 89% [12] 
 TSC1 96% [12] 
  TSC2 82% [12] 
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Statistical Analysis 
All data was analyzed using Stata (v13.1, College Station, TX). The categorical 
variables were reported as frequencies with percentages. Comparisons between 
categorical variables were performed using contingency tests (chi-square or Fisher 
exact). The diagnostic yields were described as proportions with 95% confidence 
intervals (CI) that were calculated as described by Wilson et al. [28]. These proportions 
were compared between groups using a two-sample proportion test. Statistical 
significance was assumed at a Type I error rate of 5%. 
 
Results 
Study Cohort  
There were 931 records in the database maintained by the Medical Genetics 
Department at the University of Texas McGovern Medical School during the study 
period. Of these 931 subjects, 140 were excluded for not having a structural abnormality 
potentially detectable by ultrasound. Of the 791 remaining subjects, 100 individuals did 
not undergo genetic testing and were thus excluded from further analysis. There were a 
range of reasons for not pursuing genetic testing, including denial by insurance, loss to 
follow up, parental denial, lack of concern for a genetic condition, and in some cases, no 
results were available despite the indication that a patient underwent testing. This left 
691 study that met inclusion criteria (Figure 1)  
An etiology for structural abnormalities was identified for 323 individuals in our 
population with structural abnormalities, of which 222 individuals had an identified 
genetic condition presumed to cause their structural abnormalities (Figure 2). 
Additionally, twenty six individuals were given a clinical diagnosis (Table 3).
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Figure 1: Breakdown of study cohort by testing and genetic aberration type 
12 
 
 
Figure 2: Etiology of structural abnormalities 
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Table 3: Clinical Diagnoses 
Adams Oliver syndrome 
Adrenal insufficiency 
Beckwith-Wiedemann syndrome 
Blue rubber bleb nevus syndrome (with rectal prolapse) 
Campomelic dysplasia 
Early infantile epileptic encephalopathy, type 5 (SPTAN1 mutation) 
Epidermolysis Bullosa 
GLUT1 deficiency 
Infantile cortical hyperostosis (Caffey's disease) 
Kniest chondrodystrophy 
Metaphyseal dysplasia 
Non-syndromic autosomal dominant polydactyly (x2) 
Oculo-Auriculo-Vertebral spectrum 
Opitz GBBB syndrome type 2 
Osteogenesis imperfecta 
Popliteal Ptyergium Syndrome 
Proximal focal femoral deficiency (PFFD) 
Prune-Belly syndrome 
Pseudohypoaldosteronism type 2 
Septo optic dysplasia (x2) 
Spondylothoracic dysostosis 
Thanatophoric dysplasia (x2) 
Tuberous sclerosis complex (TSC) 
 
Of the 691 patients that underwent genetic testing, 270 (39.1%) had a negative 
result and 421 (60.9%) had a positive result. Of those with a positive result, 222 (52.7%) 
were pathogenic and attributed to the phenotype of the patient. There were 151 (35.9%) 
patients with one or more benign findings on genetic testing and 48 (11.4%) patients 
with one or more uncertain results (such as a variant of uncertain significance in one or 
more genes that could be related to phenotype), which were classified as “possible” 
(Figure 1). There were 23 (5.5%) patients with a clinically significant finding presumably 
unrelated to the structural abnormality on genetic testing (Table 4).  
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Table 4: Non-causative clinically relevant findings 
Klinefelter syndrome  
    (x3 individuals; One mosaic individual) 
Hereditary Breast and Ovarian Cancer Syndrome (HBOC)  
    (x2: One patient had a deletion including BRCA2; the other had a point mutation in BRCA2)  
Disorder of Sexual Development /Discordant genitalia  
    (x2: one patient 46, XX with male genitalia; one patient 46, XY with female genitalia) 
48, XXYY syndrome 
COL3A1 pathogenic variant, Vascular EDS (type IV EDS) 
Mitochondrial disease of tRNA Ser (MELAS due to MT-TS1 mutation) 
Biallelic HADB mutations (mitochondrial trifunctional protein deficiency) 
Becker Muscular Dystrophy due to 0.145 Mb deletion at Xp21.1 encompassing dystrophin gene 
Autosomal dominant polycystic kidney disease (ADPKD) 
Axenfield-Rieger syndrome type 3 
SPTAN1 mutation, Early infantile epileptic encephalopathy, type 5 
Factor VIII deficiency 
von Willebrand disease (from other workup) 
Copy number loss at 1p31.1 (that father also has) associated with dilated cardiomyopathy 
Alpha thalassemia trait 
Additional SHOX gene due to gain at Xp22.33 
Triple X (47, XXX) 
9.399 Mb deletion of Xq27, increasing risk for developmental delay  
 
 In patients without an identified pathogenic mutation to explain their structural 
abnormalities and no other determined etiology, only 10.9% had comprehensive testing 
(CMA and WES). A majority of the patients (89.1%) at least underwent a CMA, with only 
12.2% undergoing WES.  
 
Potential Diagnostic Yield 
The potential yield for each test was broken down in the following ways: first, the 
potential yield was calculated based on the number of individuals with a genetic 
aberration identifiable by the test, including causative and benign findings. Second, the 
diagnostic yield was refined for pathogenic variants that were described as causative of 
an individual’s structural abnormalities.  
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When refined to pathogenic variants, CMA had the highest potential diagnostic 
yield of all the available prenatal testing and screening options included in this study 
[26.8% (95% CI: 23.5 -30.3)], followed by whole genome NIPT [21.2% (95% CI:  18.4 – 
24.2)] karyotype [20.8% (95% CI: 17.8 – 24.0)], NIPT+CNVs [17.9% (95% CI: 15.3 -  
20.9)], FISH [16.1% (95% CI: 13.5 - 19.1)], NIPT+ SCA [15.9% (95% CI: 13.4 - 18.9)], 
WES [15.1% (95% CI: 11.3 - 19.7)], NIPT [13.7% (95% CI: 11.3 - 16.6)], Methylation 
studies [2.4% (95% CI: 1.1 - 5.1)], NIPT+ SGD [2.3% (95% CI: 1.1 - 4.7)] and triplet 
repeat analysis [1.3% (95% CI: 0.4 - 3.8)], (Table 5, Figure 3).  
In addition to having the highest diagnostic yield, CMA was also significantly 
more likely to identify a non-causative aberration compared to all other tests (p <0.001) 
(Table 6), while WES was significantly more likely to identify a non-causative aberration 
compared to all other testing options except CMA (p= 0.013). Almost half (43%) of the 
findings identified by CMA were non-causative aberrations and 16% of the aberrations 
identified by WES were non-causative, compared to the 0-6% non-causative findings 
identified on all other tests. 
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Table 5: Potential diagnostic yield of prenatal testing for entire cohort 
Test Denominator DRT* 
All Findings  Causative, Pathogenic Findings 
NALL ꝉ ꝉ  DY**, % (95% CIꝉ )   NPOT ꝉ ꝉ  DY**, % (95% CIꝉ ) 
Screening tests        
  NIPT ꝉ 658 0.994 91 13.7 (11.3 - 16.6)  91 13.7 (11.3 - 16.6) 
  NIPT+ SCA ꝉ 658 0.989 111 16.7 (14.1 - 19.7)  106 15.9 (13.4 - 18.9) 
  NIPT +CNV ꝉ 655 0.911 134 18.6 (16.0 - 21.6)  129 17.9 (15.3 - 20.9) 
  Whole genome NIPT 655 0.918 157 22.0 (19.2 - 25.1)  151 21.2 (18.4 - 24.2) 
  NIPT + SGDꝉ 279 0.914 7 2.3 (1.1 - 4.7)  7 2.3 (1.1 - 4.7) 
Diagnostic tests        
  FISH ꝉ 658 1 111 16.9 (14.2 - 19.9)  106 16.1 (13.5 - 19.1) 
  Karyotype 655 1 145 22.1 (19.1 - 25.5)  136 20.8 (17.8 - 24.0) 
  CMA ꝉ 639 1 323 50.5 (46.7 - 54.4)  171 26.8 (23.5 - 30.3) 
  WES ꝉ 279 1 50 17.9 (13.9 - 22.9)  42 15.1 (11.3 - 19.7) 
  Methylation studies 250 1 6 2.4 (1.1 - 5.1)  6 2.4 (1.1 - 5.1) 
  Triplet repeat analysis 228 1 3 1.3 (0.4 - 3.8)   3 1.3 (0.4 - 3.8)  
* DRT = Detection Rate of the test (For screening test: previously reported detection rate x prevalence of condition in cohort; For 
diagnostic tests: assumed to be 100%)  
ꝉꝉ  NALL = number of patients with a genetic aberration that could have potentially been identified by the test ; NPOT =  number of 
patients with a causative genetic aberration that could have potentially been identified by the test 
** DY = Diagnostic yield, (Numerator/Denominator) x DR x 100 
ꝉ NIPT = Non-invasive prenatal test ; SCA= sex chromosome aneuploidy ; CNV = copy number variant ; SGD = single gene 
disorder; FISH = Fluorescent in situ hybridization; CMA = chromosomal microarray ; WES = whole exome sequencing ; CI = 
confidence interval 
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 Table 6: p-values of prenatal testing for entire cohort 
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NIPT 0.261 0.037 <0.001 <0.001 0.222 0.001 <0.001 0.574 <0.001 <0.001 
NIPT+ SCA   0.334 0.014 <0.001 0.921 0.022 <0.001 0.758 <0.001 <0.001 
NIPT+ CNV     0.132 <0.001 0.385 0.184 <0.001 0.298 <0.001 <0.001 
Whole genome NIPT       <0.001 0.018 0.859 0.018 0.031 <0.001 <0.001 
NIPT +SGD         <0.001 <0.001 <0.001 <0.001 0.940 0.406 
FISH           0.028 <0.001 0.701 <0.001 <0.001 
Karyotype             0.011 0.043 <0.001 <0.001 
CMA               <0.001 <0.001 <0.001 
WES                 <0.001 <0.001 
Methylation studies                   0.376 
Table 6: p-values of two-sample proportion test between the potential detection rates of each prenatal test among the entire study cohort. 
Statistical significance was assumed at a Type I error rate of 5%. Values bolded indicate statistical significance. 
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Figure 3: Potential diagnostic yield of prenatal testing options for entire cohort 
Study Cohort: Isolated structural abnormality vs multiple structural abnormalities 
Of the 791 individuals in the cohort who had one or more structural 
abnormalities, 143 (18.1%) had an isolated abnormality and 648 (81.9%) had multiple 
structural abnormalities (MSA) (two or more structural abnormalities). Of 143 the 
individuals with an isolated structural abnormality, 115 (80.4%) underwent genetic 
testing. Of these individuals 23 (20.0%) had a pathogenic result that explained their 
phenotype (Figure 4). 
Of the 642 individuals with MSA, 576 (88.9%) underwent genetic testing. This 
was significantly greater than the 80.4% testing rate among individuals with an isolated 
structural abnormality (p=0.0057). Of these individuals, 199 (34.4%) had pathogenic 
results that explained their phenotype (Figure 5).
The potential diagnostic yield of each prenatal testing option is depicted by the bar graph. 
Darker bars indicate the potential yield of pathogenic mutations presumed causative of an 
individual’s structural abnormalities. The light bars indicate the additional yield of non-
causative findings, which include benign findings, uncertain findings, and clinically significant 
findings presumed unrelated to the structural abnormalities. An asterisk (*) indicates a p-value 
less than 0.05 in two proportion comparison between CMA and every other test for both 
causative and non-causative aberrations potential yield.  
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Figure 4: Breakdown of isolated cohort by testing and type of genetic aberration 
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Figure 5: Breakdown of MSA cohort by testing and type of genetic aberration 
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Potential Diagnostic Yield: 
 The potential diagnostic yield for each test was broken down in the same manner 
as for the entire cohort. In the isolated cohort, WES had the highest potential diagnostic 
yield for causative aberrations 25.9% (95% CI: 13.2 - 44.7), followed by CMA 14.9% 
(95% CI: 9.2 - 23.1), (Table 7, Table 8). In the MSA cohort, CMA had the highest 
potential diagnostic yield of 29.0% (95% CI: 25.3 – 33.0), followed by whole genome 
NIPT 23.2% (95% CI: 21.8 – 29.0). 
In addition to having the highest diagnostic yield, CMA was also significantly 
more likely to identify a non-causative aberration compared to all other tests (p <0.001). 
WES was also significantly more likely to identify a non-causative aberration compared 
to all other testing options except CMA (p = 0.001). Similar to the entire cohort, almost 
half (45%) of the findings identified by CMA were non-causative aberrations and 19% of 
the aberrations identified by WES were non-causative, compared to the 0-5% of non-
causative findings identified by all other tests (Table 9, Table 10).  
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Table 7: Potential diagnostic yield of prenatal testing in individuals with an isolated structural abnormality 
Test Denominator DRT* 
All Findings   Causative, Pathogenic Findings 
NALL ꝉꝉ 
DY**, % (95% 
CIꝉ) 
  NPOT ꝉꝉ DY**, % (95% CIꝉ) 
Screening tests        
   NIPT ꝉ 105 0.997 7 6.6 (3.3 – 13.1)  7 6.6 (3.3 – 13.1) 
   NIPT+ SCA ꝉ 105 0.988 10 9.4 (5.2 – 16.7)  9 8.5 (4.6 - 15.5) 
   NIPT +CNV ꝉ 104 0.907 12 10.5 (6.7 – 19.1)  11 9.6 (6.0 – 18.0) 
   Whole genome NIPT 104 0.911 13 11.4 (7.5-20.2)  12 10.5 (6.7 -19.1) 
   NIPT + SGDꝉ  27 0.820 1 3.0 (0.7 - 18.3)  1 3.0 (0.7 - 18.3) 
Diagnostic tests        
   FISH ꝉ 105 1.000 11 10.5 (6.0-17.8)  10 9.5 (5.3 – 16.6) 
   Karyotype 104 1.000 14 13.5 (8.2 - 21.3)  11 10.6 (6.0 – 16.6) 
   CMA ꝉ 101 1.000 43 
42.6 (33.4 – 
52.3) 
 15 14.9 (9.2 – 23.1) 
   WES ꝉ 27 1.000 7 25.9 (13.1 - 44.7)  7 25.9 (13.2 - 44.7) 
   Methylation studies 27 1.000 0 0.0 (0 - 0)  0 0.0 (0 - 0) 
   Triplet repeat analysis 23 1.000 1 4.3 (0.8 -21.0)   1 4.3 (0.8 – 21.0) 
* DRT = Detection Rate of the test (For screening test: previously reported detection rate x prevalence of condition in cohort; For 
diagnostic tests: assumed to be 100%)  
ꝉꝉ  NALL = number of patients with a genetic aberration that could have potentially been identified by the test ; NPOT =  number of 
patients with a causative genetic aberration that could have potentially been identified by the test 
** DY = Diagnostic yield, (Numerator/Denominator) x DR x 100 
ꝉ NIPT = Non-invasive prenatal test ; SCA= sex chromosome aneuploidy ; CNV = copy number variant ; SGD = single gene 
disorder; FISH = Fluorescent in situ hybridization; CMA = chromosomal microarray ; WES = whole exome sequencing ; CI = 
confidence interval 
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Table 8: p-values of prenatal testing in individuals with an isolated structural abnormality 
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NIPT 0.602 0.427 0.313 0.478 0.440 0.302 0.054 0.004 0.170 0.678 
NIPT+SCA  0.782 0.622 0.329 0.800 0.605 0.152 0.013 0.117 0.495 
NIPT+CNV   0.829 0.266 0.980 0.811 0.247 0.025 0.094 0.413 
Whole genome NIPT    0.224 0.810 0.981 0.344 0.038 0.079 0.356 
NIPT + SGD     0.271 0.220 0.096 0.017 0.365 0.806 
FISH      0.791 0.236 0.023 0.096 0.420 
Karyotype       0.356 0.040 0.077 0.350 
CMA        0.179 0.033 0.172 
WES         0.005 0.038 
Methylation studies          0.277 
Table 8: p-values of two-sample proportion test between the potential detection rates of each prenatal test among the isolated study 
cohort. Statistical significance was assumed at a Type I error rate of 5%. Values bolded indicate statistical significance. 
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Table  9: Potential diagnostic yield of prenatal testing in individuals with MSA 
Test Denominator DRT* 
All Findings  Causative Findings 
NALL ꝉꝉ DY**, % (95% CIꝉ)   NPOT ꝉꝉ DY**, % (95% CIꝉ) 
Screening tests         
   NIPT ꝉ 553 0.994 84 15.1 (12.4 - 18.4) 
 84 15.1 (12.4 - 18.4)  
   NIPT+ SCA ꝉ 553 0.989 101 18.1 (15.3 - 21.7)  97 17.54(14.6 - 21.0)  
   NIPT +CNV ꝉ 551 0.911 122 20.2 (18.9 - 25.9)  118 19.5 (18.2 - 25.0)  
   Whole genome NIPT 551 0.919 144 24.0 (22.6 - 30.0)  139 23.2 (21.8 - 29.0)  
   NIPT + SGDꝉ  252 0.930 6 2.2 (1.1 -5.1) 
 5 2.2 (1.1 -5.1)  
Diagnostic tests     
  
  
   FISH ꝉ 553 1 100 18.1 (15.1 - 21.5)  96 17.4 (14.4 - 20.7)  
   Karyotype 551 1 131 23.8 (20.4 - 27.5) 
 125 22.7 (19.4 - 26.4)  
   CMA ꝉ 538 1 808 52.0 (47.8 - 56.2)  156 29.0 (25.3 - 33.0)  
   WES ꝉ 252 1 43 17.1 (12.9 - 22.2)  35 13.9 (10.2 - 18.7)  
   Methylation studies 223 1 6 2.7 (1.2 - 5.7)  6 2.7 (1.2 - 5.7)  
   Triplet repeat analysis 205 1 2 1.0 (0.3 - 3.5) 
 2 1.0 (0.3 - 3.5)   
* DRT = Detection Rate of the test (For screening test: previously reported detection rate x prevalence of condition in cohort; For 
diagnostic tests: assumed to be 100%)   
ꝉꝉ  NALL = number of patients with a genetic aberration that could have potentially been identified by the test ; NPOT =  number of patients 
with a causative genetic aberration that could have potentially been identified by the test 
** DY = Diagnostic yield, (Numerator/Denominator) x DR x 100 
ꝉ NIPT = Non-invasive prenatal test ; SCA= sex chromosome aneuploidy ; CNV = copy number variant ; SGD = single gene disorder; 
FISH = Fluorescent in situ hybridization; CMA = chromosomal microarray ; WES = whole exome sequencing ; CI = confidence interval 
MSA = multiple structural abnormalities, two or more structural abnormalities 
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Table 10: p-values of prenatal testing in individuals with MSA 
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NIPT 0.300 0.053 0.001 <0.001 0.300 0.001 <0.001 0.656 <0.001 <0.001 
NIPT+ SCA  0.368 0.016 <0.001 1.000 0.028 <0.001 0.213 <0.001 <0.001 
NIPT+ CNV   0.134 <0.001 0.368 0.193 <0.001 0.054 <0.001 <0.001 
Whole genome NIPT    <0.001 0.017 0.844 0.029 0.002 <0.001 <0.001 
NIPT+ SGD     <0.001 <0.001 <0.001 <0.001 0.724 0.318 
FISH      0.028 <0.001 0.213 <0.001 <0.001 
Karyotype       <0.001 0.213 <0.001 <0.001 
CMA        <0.001 <0.001 <0.001 
WES         <0.001 <0.001 
Methylation studies 
         0.197 
Table 10: p-values of two-sample proportion test between the potential detection rates of each prenatal test among the MSA study 
cohort. Statistical significance was assumed at a Type I error rate of 5%. Values bolded indicate statistical significance. 
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The potential yield of each prenatal testing option is depicted by the bars. The light grey bars 
indicate the yield of a test in the isolated structural abnormalities cohort and the dark grey bars 
indicate the same in the multiple structural abnormalities cohort. Listed p-values are significant 
differences in the potential yield of testing modalities between the MSA and isolated cohorts. 
Those not listed did not reach significance. 
 
Comparison of isolated cohort to MSA cohort 
 The potential diagnostic yield was significantly higher for all test types in 
individuals with MSA compared to individuals with an isolated strucutral abnormality 
except NIPT+SGD, WES, methylation studies and repeat analysis (Figure 6). For these 
tests, there were no significant differences in diagnostic yield based on isolated or 
multiple structural abnormalities. 
 
Figure 6: Potential diagnostic yield of prenatal testing options in isolated and MSA 
cohorts 
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Discussion 
Chromosome Abnormalities 
Of the 222 patients with a causative genetic aberration identified in our study, 
164 (74%) were diagnosed with a chromosome abnormality or microdeletion or 
duplication (aneuploidy, unbalanced translocations, or copy number variants). Therefore, 
CMA had the highest potential diagnostic yield across the entire cohort compared to 
other prenatal screening and testing options. CMA also had a significantly higher 
diagnostic yield among individuals with MSA compared to an isolated structural 
abnormality (p = 0.003), indicating a high incidence of chromosome abnormalities in the 
presence of MSA. This is consistent with previous studies comparing CMA and 
karyotype, studies comparing CMA to NIPT, and studies comparing CMA in pregnancies 
with isolated vs. multiple anomalies [4, 17, 24].   
Not surprisingly, the potential diagnostic yield of CMA was significantly greater 
than all NIPT screening options, including whole genome NIPT (p =0.018), further 
supporting the recommendation to use diagnostic testing over screening methods after 
identification of an ultrasound abnormality [2, 18]. Assuming data on detection rates for 
whole genome are accurate, there is potentially a loss of 5.6% of prenatal diagnoses if 
whole genome NIPT is used over CMA after identification of one or more structural 
abnormalities. This is important to discuss when reviewing test options, as the difference 
in diagnostic yield might influence whether a patient to chooses an invasive procedure 
over a screening procedure. 
Due to the high rate of chromosome abnormalities and microdeletions and 
microduplications detected in our cohort, whole genome NIPT had the second highest 
potential yield in this study and karyotype had the third highest potential yield, but these 
were not significantly different from each other (p=0.845). From this data, one could 
extrapolate that whole genome NIPT provides an overall yield comparable to a 
karyotype. However, until sufficient data is published in peer reviewed journals 
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supporting high sensitivity and specificity claimed in the current literature for whole 
genome NIPT one may wish to proceed with caution at equivocating the two [13].  
 
Single gene disorders 
 Forty-two patients were found to have a single gene disorder in our cohort 
(18.9%) that could be detected by a sequencing test, such as whole exome sequencing, 
but would not be found on a CMA or whole genome NIPT. The potential diagnostic yield 
of prenatal WES across our isolated and MSA, corresponds with the previously reported 
prenatal WES yield of 6.2-80% [5-8].  The predicted diagnostic yield from this study 
could potentially be lower in practice in a prenatal population, as the patients were 
evaluated after delivery and thus could have had additional clinical indications to suggest 
a single gene disorder that would not have been detected on a prenatal ultrasound. 
WES findings were detected in 35 different genes, of which only 7 could have 
been screened by clinically available NIPT+SGD. This was reflected in the significant 
differences in potential diagnostic yield for prenatal WES and NIPT+SGD in both the 
isolated structural abnormality cohort [25.9% vs 3.0%], and MSA cohort [13.9% vs 
2.2%]. While NIPT+SGD provides another avenue to identify individuals with a single 
gene disorder, the use of this test is limited to the specific genes on the panel and 
conditions that are de novo or paternally inherited. In addition, the only data available on 
this clinically available test is a single white paper and the detection rates quoted range 
from 43-99% [16]. These are important limitations to stress during pre-test counseling. 
Due to the challenge of obtaining insurance coverage for prenatal whole exome 
sequencing, we sought to identify sequencing panels that could identify the genetic 
aberration in our single gene diagnosis category. We were able to identify available 
prenatal sequencing panels for 22 of the 35 different genes, which could have potentially 
provided a diagnosis for 29 out of the 42 (69.0%) individuals with an identified single 
gene disorder. The remaining 31% of these individuals could only have been identified 
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by prenatal WES. This demonstrates the utility of prenatal WES and the need for 
insurance coverage of prenatal WES after identification of one or more structural 
abnormalities on ultrasound. 
 
Incidental and Uncertain Findings 
In addition to the highest potential diagnostic yield, CMA had the highest rate of 
benign or uncertain results compared to all screening counterparts and other diagnostic 
tests (p<0.001). This is an important component of pre-test counseling to ensure there is 
a full consent to the testing type and the possibility of identifying a result that is either not 
causative of the identified structural abnormalities, an incidental finding, or variant of 
uncertain significance that could potentially provide an answer in the future or not. 
WES had the second highest rate of benign or uncertain findings compared to 
other screening and diagnostic tests (p = 0.013). The higher rate of incidental findings on 
WES in our study cohort might be lower in a prenatal population, as the reporting is 
slightly different. Prenatal WES reports are typically focused on genes known to cause 
abnormalities noted in the clinical indication. Reports can include variants of uncertain 
significance and secondary findings. Our study cohort had 8 individuals with a finding 
potentially identifiable on prenatal WES that were not causative aberrations. Prenatal 
reporting of these findings would depend upon the performing laboratory and patient 
preferences. 
Uncertain or incidental findings may also be identified through NIPT but due to 
variable reporting practices by NIPT laboratories we are unable to quantify how often 
these incidental findings may be detected and reported by a screening test. 
 
Utilization of diagnostic yield in clinical settings 
 Discussions about prenatal testing options after the identification of one or more 
structural abnormalities should include a discussion of the risks, benefits and limitations 
30 
 
of genetic testing to allow for well-informed and autonomous patient decision-making. 
The diagnostic yields described in this study should be used as a baseline for this pre-
test counseling. There are many other factors that should be considered in addition to 
potential diagnostic yield, including the differential diagnosis, patient desire for 
information, cost of testing/insurance coverage compared to the increase in yield, the 
potential for uncertain, incidental, or secondary findings, and the positive predictive value 
of testing. In addition, clinicians should also integrate relevant information such age, 
family history, and abnormalities identified to help direct testing recommendations.  
 
Strengths and Limitations 
Our study included a large population of infants who were seen by board certified 
medical geneticists in a large tertiary care, academic medical center. This setting 
allowed for a large study cohort of patients that underwent accurate postnatal 
assessments, but as in any retrospective chart review, ours was limited by information 
recorded in the electronic medical record. The patients in this study were first seen by 
the medical genetics team between January 2014 and December 2017, which should 
have allowed adequate time for full genetic workup by the time of data collection in fall 
2018. 
However, not every individual received the recommended workup due to 
insurance denials or loss to follow up. Furthermore, testing strategies utilized by 
healthcare providers are influenced by the clinical presentation, family history, cost 
considerations (including insurance), patient follow-up, and results of any other testing 
done. Since our data on the yield of the tests relies on which tests were or were not 
performed in our cohort, factors that influence testing might act as potential confounders 
and/or effect modifiers in our analysis. This is highlighted by the 77% (n=306, 95% CI: 
73.10 – 81.31) who did not have a comprehensive workup (CMA & WES)  
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Additionally, the diagnostic yield experienced in a prenatal testing setting may not 
be equivalent due to postnatal ascertainment bias. Structural abnormalities were 
included in this study if they had the potential to be detected by prenatal ultrasound. We 
did not confirm that all structural abnormalities were in fact detected prenatally. Some 
structural abnormalities may not be detected on routine ultrasound or by all ultrasound 
centers and thus the classification of a patients as having an isolated or multiple 
structural abnormalities may differ between institutions, and thus the potential diagnostic 
yield of testing will vary as a function of the skills of the sonographers and the nature of 
the defects. 
In order to evaluate diagnostic yields reflective of screening tests, prenatal 
screening test sensitivities were determined using current literature, which leads to some 
limitations. For some of the conditions on these screens, such as Down syndrome, 
robust data exists from which we were able to obtain well supported detection rates. For 
conditions that have been added to screening tests more recently, such as microdeletion 
syndromes and select autosomal dominant single gene disorders, data regarding the 
sensitivity of testing is not as widely available nor is it nearly as well established.  
Despite these limitations, this study includes the most prenatal screening and 
diagnostic options available in clinical settings than any other previous study, providing a 
more robust look at the potential diagnostic yield of all prenatal testing options available.  
Conclusions 
 
 The data presented here provide further evidence that CMA has the highest 
potential diagnostic yield among all current prenatal testing options after identification of 
one or more structural abnormalities on ultrasound. Additionally, CMA also had the 
highest rate of non-causative (benign, uncertain, or incidental) results. As expected, 
screening tests had a lower potential yield compared to CMA. Expanded NIPT 
(NIPT+CNVs and whole genome NIPT) had a higher potential yield than traditional NIPT 
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and whole genome NIPT had a comparable yield as a karyotype. While interesting, it is 
important to consider the limited data on expanded NIPT and how this might affect study 
results and post-test counseling regarding screening results. When deciding which 
testing options to pursue, patients should be counseled about the differences in potential 
yield of testing among diagnostic and screening tests, and be informed of the potential of 
obtaining a result that is uncertain or considered incidental. Further investigation into the 
potential yield of expanded NIPT panels and prenatal WES should be explored.  
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Appendix 
Supplemental Table 1: Pathogenic findings presumed causative of structural abnormalities 
Aneuploidies n Iso MSA Mos FISH/Karyotype/CMA result   
Monosomy X (Turner syndrome) 8 2 6 1 45, X ; 45,X/46, XX  
Monosomy X (ring X) 2  2 2 45, X/46, X, +r   
Monosomy X/ 46, XY 2  2 2 45, X/ 46, XY  
Triploidy 1  1  69, XXX  
Trisomy 13 3  3  47, XX, +13 (47, XY, +13)  
Trisomy 16 1  1 1 47, XY, +16 /46, XY  
Trisomy 18 11  11  47, XX, +18 (47, XY, +18)  
Trisomy 21 68 6 62  47, XX, +21 (47, XY, +21)  
49, XXXXY 2 1 1   49, XXXXY   
Total  98 8  89        
       
Unbalanced translocation/chromosome rearrangements n Iso MSA Mos Karyotype/CMA result 
Monosomy X (Turner syndrome) 1  1  46, X, der(X)t(X;7)(q24;q22) 
Monosomy X and isodicentric Y  1  1 1 45,X[26]/46,X, psu idic(Y)(q11.23)[4] 
Tetrasomy isochromosome 12p (Pallister-Killian) 1  1 1 Tetrasomy 12p 
Trisomy 13 1  1  46, XY, +13, der(13;14)(q10;q10) 
Trisomy 18 1  1  46, XX, der(3)t(3;18)(p26.1;q11.2) 
Trisomy 21 3  3 1 46, XX, +21, der(21;21)(q10;q10) 
 1  1  46, XY, +21 der(21;21)(q10;q10) 
 1 1   46, XX, +21, der(13;21)(q10;q10)  
Complex chromosome 8 rearrangement 1  1  
8p23.3p23.1(194617-8403434)x1, 8p23.1p12(12580104-33119221)x3, 
8q24.12q24.3(121831416-146294241)x3 
Derivative chromosome 12 with terminal duplication 1  1  
12p13.33p13.32(189216-3454991)x1, 12p13.32p12.1(3523313-
23666601)x3 
1q deletion and 9p duplication 1  1  9p duplication, 1q deletion 
4q terminal deletion and 8q terminal duplication 1  1  46,XX,der(4);t(4,8)(q35.2-24.3) 
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5p deletion and 9p duplication  1  1  5p15.33p15.2(113576-11410194)x1, 9p24.3p22.2(203861-18301446)x3 
Partial trisomy 5p  1  1  46, XX, add 5p15.2 
5 and 12 1  1  Unbalanced translocation between chromosomes 5 and 12 
Partial 7q duplication 1  1  partial 7q duplication 
9p deletion and 4q duplication 1  1  
4q32.3q35.2(164780923-190791227)x3, 9p24.3p22.3(207454-
14746829)x1 
10q26.12 deletion and 3p26.3 duplication 1  1  46, XX, der(10)t(3;10)(p25.1;q26.12) 
1q32-q41 and q41;qter duplication, and 10q terminal 
deletion 1   1   
1q32-q41 duplication, 1q41;qter duplication, 10q terminal deletion 
  
Total 21 1  20        
       
Copy Number Variants n Iso MSA Mos CMA result Size (range) 
1p31.1-31.2 interstitial deletion 1  1  1p31.1p32.1 interstitial deletion 13.35 Mb 
1p34 deletion 1  1  1p34.1p32.3 deletion (45748571-54527813) 8.779 Mb 
1p36 deletion syndrome 2  2  1p36.3 deletion 3.4-9.736 Mb 
1q43 deletion syndrome 3 1 2  1q43q44 deletion 4.88-12.1 Mb 
2p23.3p25.1 deletion 1  1 1 2p23.3p25.1 deletion 15.8 Mb 
2q22.1q33.2 deletion syndrome 1 1   2q33.1q33.2 deletion (199710981-204484143) 4.773 Mb 
3q deletion syndrome 1  1  3q deletion  
3q26.32q29 duplication 1  1  3q26.31q29 duplication (174251329-197717518)  23.47 Mb 
4q31.3 deletion syndrome 2  2  4q31.3 deletion 38-38.392 Mb 
7q11.23 deletion (Williams syndrome) 1 1   7q11.23 deletion (72744494-74142327) 1.3 Mb 
7q22.3 deletion 1  1  7p22.3 deletion (1-2759647) 2.760 Mb 
7q36.2 deletion 1  1  7q36.2 deletion (153584506-153647972) 0.063 Mb 
8q11.21q12.1 deletion 1  1  8q11.23q12.1 deletion (54871180-58883606) 4.012 Mb 
9q34.3 deletion (Kleefstra Syndrome) 1  1  9q34.3 deletion (139876171-141213421) 1.337 Mb 
13q12.3q13.2 deletion 1  1  13q12.3q13.2 deletion (28933097-35163380) 6.230 Mb 
14q32.31 deletion  1  1  14q32.31 deletion   
15q11.2q13.3 deletion (Prader Willi syndrome) 1  1  15q11.2q13.3 deletion 10.75 Mb 
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15q21.2 deletion 1  1  15q21.2q22.2 deletion (50833347-61673964)  10.841 Mb 
15q26.2-q26.3 deletion 1  1  15q26.2-q26.3 deletion (95462599-102354857) 7.096 Mb 
16p13.3 deletion 1  1  16p13.3 deletion (3639643-4261338) 0.622 Mb 
16q12.2 deletion 1  1  16q12.2q21 deletion (54514235-64397522) 9.883 Mb 
17p13.3 deletion (Miller-Dieker syndrome) 1  1  17p13.3p13.2 deletion (1-5559951) 5.487 Mb 
18q11.2 interstitial deletion 1  1  18q11.2 deletion 0.518 Mb 
21q22.3 deletion 1  1  21q22.3 deletion (43619800-48157577) 4.5 Mb 
22q11.21 deletion syndrome (DiGeorge syndrome)  19 2 17  22q11.21 deletion 2.762 - 5.747 Mb 
22q13.31q13.33 deletion (Phelan McDermid) 1  1  22q13.31q13.33 deletion (47388907-51304566) 3.916 Mb 
Xp11.4 deletion 1   1   Xp11.4 deletion (41589371-41599075) 0.010 Mb 
Total 49 5  44        
       
Single gene disorders n Iso MSA Mos Gene and coding change(s) 
3-methylglutaconic aciduria type VII  1  1  CLPB: c.[1156+1G>A] ; [1156+1G>A]  
Achondrogenesis type 2 or hypochondrogenesis 1  1  COL2A1: c.1587G>A (p.Gly513Ser)  
Adams-Oliver syndrome 1  1  NOTCH1: c.166C>T (p.R56*)  
Androgen insensitivity 1  1  AR: c.2659A>G (p.M887V)  
Antley-Bixlar syndrome (POR deficiency) 1  1  POR: c.859G>C (p.Ala287Pro)  
ARX related disorder 1  1  ARX: c.1295_ 1317dup23 (p.A440fs)  
Autosomal Recessive Polycystic Kidney Disease 
(ARPKD) 1  1  PKHD1: c.[3761_3762delCCinsG] ; [5895dupA]  
Beckwith-Wiedemann Syndrome (BWS) 1  1  CDKN1C: c.189C>G (p.Tyr63*)  
Brain-Lung-Thyroid Syndrome 1  1  NKX2-1: c.390C>G (p.Y130X)  
BRAT1 syndrome (Rigiddty and multifocal seizure 
syndrome, leathal neonatal) 1  1  BRAT1: c.[1710delG] ; [566dupG]  
Campomelic dysplasia 2  2  SOX9:c.628_638dup11  
     SOX9: c.55delT  
CHARGE syndrome 2  2  CHD7: c.779_780delCC (p.P260fs)   
     CHD7: c.3065_3066dupTT (p.A1023Lfs*20)  
Congenital Adrenal Hyperplasia (CAH) 1  1  
CYP21: In2G mutation and large gene conversion due to 30 kb deletion of 
CYP21A1P and CYP21A2 
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Congenital diaphragmatic hernia and heart defects, 
multiple 4 1  1  NR2F2: c.103_109delGGCGCCC (p.Gly35ArgfsTer75) 
Cystic Fibrosis 2 2   CFTR: c.[1521_1523delCTT] ; [unknown] **+ sweat test 
     CFTR: c. [1521_1523delCTT]; [1288insTA]   
Desbuquois dysplasia type 2 1  1  XYLT1: c.[2560G>T] ; [2560G>T]  
Dilated cardiomyopathy 1S 1 1   MYH7 : c.602T>C (p.I201T)  
Heterotaxy syndrome due to NODAL mutation 1  1  NODAL: c.778G>A (p.G260R)  
Hypertrichotic osteochondrodysplasia (Cantu 
syndrome) 1  1  ABCC9: c.1664T>C (p.F555S)  
Joubert syndrome type 10 1  1  OFD1: c.2668C>T (p.R890X)  
Kabuki Syndrome 1  1  KMT2D: c.10938_10939delinsT (p.P3647fs)  
Kniest dysplasia 1  1  COL2A1 pathogenic mutation  
Mandibulofacial Dysostosis, Guion-Almedia Type  1  1  EFTUD2: c.702+1G>T  
Marfan syndrome 2  2  FBN1: c.3094T>C (p.Cys1032Arg)  
     FBN1: c.4188delA  (p.Gly1397Valfs*16)  
Morquio Syndrome A (MPS 4) 2 1 1  GALNS: c. [633+1G>C ]; [1558T>C] *sibs  
Multiple Endocrine Neoplasia type 2 (MEN2) 1 1   RET: c.1144C>T (p.Gln382*)  
Noonan syndrome 1  1  PTPN11: c.854T>C (p.F285S)  
 1  1  HRAS: c.34G>A (p.G12S)  
Osteogenesis Imperfecta type III 1  1  COL1A2: c.821G>A (p.Gly274Asp)  
Pfeiffer syndrome type 3 1  1  FGFR2: c.870G>T (Pro250Arg)  
Simpson-Golabi-Behmel syndrome 1  1  GPC3: c.760C>T (p.Arg254*)  
Stickler syndrome 1  1  COL2A1: c.1587G>A (p.Gly513Ser)  
TARP syndrome 1  1  RBM10: c.1473_1474delGT (p.S492Dfs*25)  
Tuberous Sclerosis Complex (TSC) 1 1   TSC2: c.2590C>T (p.Gln864X)  
X-Linked hydrocephalus  1  1  L1CAM: c.2014C>T (p.GLN672*)  
X-linked Spinal Muscular Atrophy 1  1  UBA1: c.1731C>T (p.N577N)  
ZIC3 mutation 1 1     ZIC3: c.75C>G (p.H25Q)   
Total 42  7 35        
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Methylation Disorders n Iso MSA Mos Methylation analysis   
Beckwith Wiedemann syndrome (BWS) 3  3  IC2 (LIT1) hypomethylation  
Beckwith-Wiedemann syndrome (BWS) 1  1  Paternal UPD of 11p15   
Russell Silver syndrome (RSS) 1  1  Loss of methylation at DMR1  
Prader Willi syndrome (PWS) 1  1  Maternal UPD of 15q11.2-11.3  
Total 6 0  6        
       
Triplet Repeat Disorders n Iso MSA Mos Gene, triplet repeat, number of repeats   
Congenital Myotonic Dystrophy (type 1) 2  2  DMPK: greater than 1500 CTG repeats  
Congenital Central Hypoventilation Syndrome 
(CCHS) 1 1     PHOX2B: 27 and 20 polyalanine repeats   
Total 3 1  2        
       
"Other" Disorders n Iso MSA Mos Description of defect   
Testicular Disorder of Sexual Development 1  1  46, XX (with male genitalia)  
Mosaic Trisomy 21 and Trisomy 18 1   1 1 Mosaic Trisomy 21 [70%] and Trisomy 18 [30%]   
Uniparental disomy of chromosome 20 1   1   Uniparental disomy of chromosome 20 (AOH of  chromosome 20) 
Total 3 0  3        
       
†Iso = isolated structural abnormality; MSA = multiple structural abnormalities (more than 1); Mos = Mosaic, FISH = Fluorescent in situ hybridization; 
CMA = chromosomal microarray 
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Supplemental Table 2: Structural abnormalities included in study 
Organ system  n* Isolated MSA* 
Cardiac 465 85 380 
Central nervous system  102 5 97 
Effusion 57 3 54 
Face/ear 423 7 416 
Gastrointestinal 185 11 174 
Genital 89 4 85 
Growth 180 13 167 
Head shape 138 2 136 
NT/nuchal fold/cystic hygroma 8 0 8 
Placental 13 0 13 
Prenatal 145 3 142 
Renal 78 3 75 
Skeletal 180 4 176 
Spine 65 0 65 
Thorax 40 2 38 
Umbilical 41 0 41 
Other 24 1 23 
Total 2233 143 2090 
n = number of individuals with a structural abnormality in specified 
organ system.  
MSA = multiple structural abnormalities 
*not mutually exclusive and therefore do not add up to 791 and 647 
respectively 
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